Home  >  News
Eppen_Cent_Feb24
you can get e-magazine links on WhatsApp. Click here
News
  Aadi Bioscience announces publication of long-term efficacy and safety data further supporting Fyarro to treat malignant PEComa,   March 04, 2024
  Innovent Biologics begins patient dosing in phase I study of IBI3002 in Australia,   March 02, 2024
  BioLineRx doses first patient in randomized phase 2 combination trial to evaluate CXCR4 inhibitor, motixafortide in pancreatic cancer,   March 01, 2024
  First UK patients receive experimental mRNA therapy for cancer,   March 01, 2024
  Bristol Myers Squibb announces positive results from phase 3 DAYBREAK open-label extension trial of Zeposia in patients with relapsing forms of MS,   March 01, 2024
  Intelligent Bio Solutions partners with Cliantha Research to conduct PK study as part of US FDA 510(k) pathway,   March 01, 2024
  ARTHEx Biotech gets US FDA clearance to begin phase I-IIa ArthemiR trial of ATX-01 for myotonic dystrophy type 1,   February 29, 2024
  NIH-funded study shows intervention reduces likelihood of developing postpartum anxiety and depression by more than 70%,   February 28, 2024
  Viking Therapeutics reports positive results from phase 2 VENTURE trial of dual GLP-1/GIP receptor agonist VK2735 in patients with obesity,   February 28, 2024
  Everest Medicines & Kezar Life Sciences receive China NMPA nod to begin phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritis,   February 28, 2024
  Cynata Therapeutics announces encouraging initial data from phase 1 trial of CYP-006TK to treat diabetic foot ulcer,   February 27, 2024
  Antibody reduces allergic reactions to multiple foods in NIH clinical trial,   February 27, 2024
  Survodutide phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis,   February 27, 2024
  GSK announces positive results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea,   February 27, 2024
  Immunofoco gets US FDA & China CDE approvals to begin clinical trial of IMC001 for EpCAM CAR-T targeted advanced solid tumours,   February 26, 2024
  BrainStorm seeks Special Protocol Assessment request from US FDA for phase 3b trial of NurOwn in ALS,   February 26, 2024
  Rhythm Pharma to add cohort of patients with hypothalamic obesity in Japan to its ongoing global phase 3 trial of setmelanotide,   February 26, 2024
  Biodexa announces R&D update including positive results from phase I trial of MTX110 in patients with diffuse midline glioma,   February 26, 2024
  Monopar reports positive preclinical data for its MNPR-101 radiopharma programme targeting advanced cancers,   February 24, 2024
  Notable advances volasertib phase 2 programme utilizing proprietary PPM platform-guided enrollment,   February 24, 2024

 Back
 
CEI_CPT_CLI_150x60
Pharma_India_Expo24
India Lab Expo
Copyright © 2023 Saffron Media Pvt. Ltd |